Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

Rambam Health Care Campus

Status and phase: Completed; Phase 3; Phase 2

Conditions: Pancreatic Cancer

Treatments: Drug: irinotecan, gemcitabine

Study type: Interventional

Funder types: Other

Identifiers

NCT00192712

RonIrinoGem.CTIL

Details and patient eligibility

About

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• locally advanced pancreatic cancer
• performance status 0-2
• normal blood count and chemistry
• no previous chemotherapy or radiotherapy

Exclusion criteria

• serious concurrent systemic disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)